<html><body> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human 
use   ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> annex to the ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for new drugs and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> q1c   current step 4 version dated 6 november 1996    this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich process.  at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa. 1   q1c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history  first codification history date new codification november 2005 q1c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 29 november 1995 q1c current step 4 version q1c <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 6 november 1996 q1c       2   stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> annex to the ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for new drugs and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process at the ich steering committee meeting  on 6 november 1996, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption  to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich   1. general the ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> was issued on october 27, 1993. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> is an annex to the ich parent stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> and addresses the recommendations 
on what should be submitted regarding stability of new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> by the 
owner of the original application, after the original submission for new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>.  2. new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> a new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> is defined as a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> which is a different pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> type, but <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">contains</a></span> the same active substance as included in the existing drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> by the pertinent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authority.  such pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> types include <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> of different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span> route (e.g., oral to parenteral), new specific functionality/delivery systems  (e.g., immediate release tablet to modified release tablet) and different dosage 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> of the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span> route (e.g., capsule to tablet, solution to 
suspension).  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocols</a></span> for new dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> should follow the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> in the parent stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> in principle. however, a reduced stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4821">database</a></span> at submission time (e.g., 6 months accelerated and 6 months long term data from 
ongoing studies) may be acceptable in certain justified cases.   1 </body><html>